Vantage logo

Covid-19 stalls biotech flotations

Several young drug developers managed to float in the first quarter, but new issues dried up in March when coronavirus infected the markets. Is the game back on?

Vantage logo

Covid-19 hits Europe drug stocks hardest

US drug stocks were shielded from bigger falls in the first quarter by leading coronavirus researchers, leaving groups listed in Japan and Europe to tumble harder.

Vantage logo

Covid-19 infects global drug stocks

The coronavirus pandemic wiped billions from global drug stock valuations in the first quarter, with the few gainers failing to offset huge losses elsewhere.

Vantage logo

Covid-19 forces Lilly to hit the brakes

As Lilly pauses much of its research owing to the coronavirus pandemic, Vantage takes a look at an estimate of the cash committed to ongoing clinical studies. Clue: it’s…